Prime Medicine, Inc. (PRME) Forward P/S Multiple

Public company logo of Prime Medicine (PRME)

Prime Medicine, Inc. (PRME) possesses significant pricing power potential due to its DNA prime editing method. Stable capital reserves support intensive research and development. The shift in the projected P/S ratio visualizes these expectations, where the current value is 109.50. However, fierce competition in the gene editing field and patent disputes create serious risks for the long-term sustainability of the business.

Prime Medicine - PRME Market Cap to Expected Sales Ratio (period 05/12/2024 - 11/15/2026)

PRME (Prime Medicine): analytical breakdowns and indicator data

- current price and projected stock value:
Summary company analysis:Prime Medicine Bio PRME
Product sample of primemedicine.com

Market expectation dynamics are critical for Prime Medicine, Inc. (PRME) amid fierce competition in the genome editing sector. The projected P/S metric compares current market capitalization with updated revenue forecasts to measure the premium for future growth. Daily price action regarding the projected P/S metric reflects investors' real-time assessment of patent risks and technological breakthroughs. High indicator values signal optimism, necessitating caution during sharp spikes.

Analysis of competing companies

Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|CRISPR Therapeutics Inc (CRSP) - Forward P/S Multiple|WGS (GeneDx Holdings) - Forward P/S Multiple|RARE: Forward Price to Sales|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|SRPT: Future Price to Revenue|Forward P/S Multiple TWST (Twist Bioscience Inc)|Market Cap to Expected Sales Ratio 10x Genomics Corp (TXG)|intelliatx.com - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke STOK|biolifesolutions.com (BLFS) - Price-to-Projected Revenue Ratio|WVE - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MAZE|Forward Price-to-Revenue Multiple Sionna Therapeutics, Inc. (SION)|Forward P/S Multiple TSHA|Forward P/S Multiple uniQure N.V. (QURE)|Price-to-Projected Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Projected Revenue|Solid Biosciences Inc - Forward P/S Multiple|OCGN - Forward P/S Multiple|PACB: Forward P/S Multiple|BNTC - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Design Therapeutics, Inc.|RCKT: Forward Price to Sales|Forward Price-to-Revenue Multiple FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Projected Revenue|SLN - Price-to-Projected Revenue Ratio|Projected Price to Revenue ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Forward Price-to-Revenue Multiple|Sangamo Therapeutics Inc. (SGMO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Nautilus Bio|Market Cap to Future Revenue Ratio Metagenomi Therapeutics MGX|Price-to-Projected Revenue Ratio Precision BioSciences (DTIL)|GBIO - Market Cap to Future Revenue Ratio|Forward P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Forward Price-to-Revenue Multiple|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals Corp|MBIO: Forward P/S Multiple|TransCode (RNAZ) - Forward P/S Multiple|BNGO (Bionano) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.